The multitargeted TKI sorafenib in combination with the mTOR inhibitor everolimus (Figure 2) proved to be effective in unresectable osteosarcoma progressing after standard treatment, but it did not reach the prespecified target of 6-month progression-free survival (PFS) of 50% (23) (Table 2). This evidence concerns the gene MTOR and osteosarcoma.